Log in

NASDAQ:CLGNCOLLPLANT HOLDI/S Stock Price, Forecast & News

$10.04
+0.06 (+0.60 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.00
Now: $10.04
$10.10
50-Day Range
$9.71
MA: $10.13
$10.80
52-Week Range
$3.35
Now: $10.04
$14.55
Volume6,277 shs
Average Volume4,820 shs
Market Capitalization$56.90 million
P/E RatioN/A
Dividend YieldN/A
Beta1.08
CollPlant Holdings Ltd., a regenerative medicine company, focuses on developing and commercializing tissue repair products for three-dimensional (3D) bio-printing of tissues and organs, dermal fillers for aesthetics, orthobiologics, and advanced wound care markets in the United States, Canada, and Europe. The company's products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. Its products include VergenixSTR, a soft tissue repair matrix intended for treatment of tendinopathy; VergenixFG, a wound-filling flowable gel for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; and BioInks for 3D printing of tissues and organs. CollPlant Holdings Ltd. was founded in 2004 and is headquartered in Rehovot, Israel.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.14 out of 5 stars


Industry, Sector and Symbol

Industry Surgical appliances & supplies
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CLGN
CUSIPN/A
CIKN/A
Phone972-73-232-5600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.32 million
Book Value$0.72 per share

Profitability

Net Income$-11,160,000.00
Net Margins-404.33%

Miscellaneous

Employees40
Market Cap$56.90 million
Next Earnings Date9/24/2020 (Estimated)
OptionableNot Optionable

Receive CLGN News and Ratings via Email

Sign-up to receive the latest news and ratings for CLGN and its competitors with MarketBeat's FREE daily newsletter.

COLLPLANT HOLDI/S (NASDAQ:CLGN) Frequently Asked Questions

How has COLLPLANT HOLDI/S's stock been impacted by COVID-19 (Coronavirus)?

COLLPLANT HOLDI/S's stock was trading at $10.20 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CLGN stock has decreased by 1.6% and is now trading at $10.0350. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of COLLPLANT HOLDI/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for COLLPLANT HOLDI/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for COLLPLANT HOLDI/S.

When is COLLPLANT HOLDI/S's next earnings date?

COLLPLANT HOLDI/S is scheduled to release its next quarterly earnings announcement on Thursday, September 24th 2020. View our earnings forecast for COLLPLANT HOLDI/S.

What price target have analysts set for CLGN?

1 analysts have issued 12-month price targets for COLLPLANT HOLDI/S's shares. Their forecasts range from $13.00 to $13.00. On average, they anticipate COLLPLANT HOLDI/S's share price to reach $13.00 in the next twelve months. This suggests a possible upside of 29.5% from the stock's current price. View analysts' price targets for COLLPLANT HOLDI/S.

Has COLLPLANT HOLDI/S been receiving favorable news coverage?

Press coverage about CLGN stock has been trending negative recently, according to InfoTrie Sentiment. InfoTrie identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. COLLPLANT HOLDI/S earned a daily sentiment score of -2.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the company's share price in the near future. View the latest news about COLLPLANT HOLDI/S.

Who are some of COLLPLANT HOLDI/S's key competitors?

What other stocks do shareholders of COLLPLANT HOLDI/S own?

Who are COLLPLANT HOLDI/S's key executives?

COLLPLANT HOLDI/S's management team includes the following people:
  • Prof. Oded Shoseyov, Founder & Chief Scientist Officer (Age 63)
  • Mr. Eran Rotem, Deputy CEO & CFO (Age 51)
  • Dr. Philippe David Bensimon, VP of Regulation Affairs & Quality Assurance (Age 54)
  • Dr. Nadav Orr, VP of R&D (Age 62)
  • Mr. Yehiel Tal, Chief Exec. Officer (Age 67)

When did COLLPLANT HOLDI/S IPO?

(CLGN) raised $22 million in an initial public offering (IPO) on Friday, December 9th 2016. The company issued 3,500,000 shares at $6.23 per share. Ladenburg Thalmann acted as the underwriter for the IPO and Roth Capital Partners was co-manager.

What is COLLPLANT HOLDI/S's stock symbol?

COLLPLANT HOLDI/S trades on the NASDAQ under the ticker symbol "CLGN."

How do I buy shares of COLLPLANT HOLDI/S?

Shares of CLGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is COLLPLANT HOLDI/S's stock price today?

One share of CLGN stock can currently be purchased for approximately $10.04.

How big of a company is COLLPLANT HOLDI/S?

COLLPLANT HOLDI/S has a market capitalization of $56.90 million and generates $2.32 million in revenue each year. The company earns $-11,160,000.00 in net income (profit) each year or ($1.29) on an earnings per share basis. COLLPLANT HOLDI/S employs 40 workers across the globe.

What is COLLPLANT HOLDI/S's official website?

The official website for COLLPLANT HOLDI/S is www.collplant.com.

How can I contact COLLPLANT HOLDI/S?

COLLPLANT HOLDI/S's mailing address is 4 OPPENHEIMER ST. 11TH FLOOR, REHOVOT L3, 74140. The company can be reached via phone at 972-73-232-5600 or via email at [email protected]

This page was last updated on 7/5/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.